Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 18
---
 ended September 30, 2025, we received net proceeds from the exercise
of the remaining Series A Preferred Warrants, the collection of stock subscriptions receivable and ELOC fundings of approximately $4.2
million. Furthermore, during the nine months ended September 30, 2025, we received net proceeds from the sales of Series D Preferred Stock
of approximately $2.6 million. Additional funds are necessary to maintain current operations and to continue R&D activities. However,
there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities
and planned regulatory filings with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending
and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s
business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue
as a going concern within one year from the date these financial statements are issued. These financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities
that might result from the outcome of this uncertainty.

<div align='center'>6</div>

Risks and uncertainties
– The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not
limited to, limited management resources, intense competition, and dependence upon the availability of cash to sustain operations. The
Company’s operating results may be materially affected by the foregoing factors.

The Company’s research
also requires approvals from the FDA prior to beginning clinical trials and prior to product commercialization. There can be no assurance
that the Company’s current ongoing research and future clinical development will result in the granting of these required approvals.
If the Company is denied such approvals or such approvals are substantially delayed, they could have a material adverse effect upon the
Company’s future financial results and cash flows.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation –
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the SEC. In the opinion of management,
the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are
necessary for a fair presentation of the financial position, operating results and cash flows for